CoChat
Sign Up
Cited by 177Liver Disease and TransplantationGastrointestinal motility and disordersGut microbiota and health

The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.

Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis

Open access
Pardo, Albert, Bartolí, Ramon, Lorenzo-Zúñiga, Vicente, Planas, Ramon, Viñado, Belén, Riba, Joan, Cabré, Eduard, Santos, Justiniano, Luque, Teresa, Ausina, Vicenç, Gassull, Miguel A.·2000·Hepatology
DOI 10.1053/he.2000.5746
Open this paper in CoChat — free accountOpen PDF

Abstract

Deranged intestinal motility, which occurs in cirrhosis, may facilitate the development of intestinal bacterial overgrowth (IBO), which can lead to bacterial translocation (BT). To assess the effect of cisapride on IBO and BT in cirrhosis, cirrhotic rats received cisapride or a placebo for 7 days, and measurements of jejunal bacterial content and BT studies were performed. In addition, jejunal fluid from 46 cirrhotic patients was obtained for quantitative bacterial culture. Those patients in whom gram-negative IBO was detected were randomized to receive or not to receive cisapride (20 mg twice per day) for 1 week. Cisapride significantly reduced IBO in cirrhotic rats. In addition, no BT was documented in treated animals, whereas it occurred in 40% in nontreated cirrhotic rats. Total IBO was documented in 23 of 46 cirrhotic patients, which was caused by gram-negative organisms in 10 cases. Orocecal transit time (OCT) significantly decreased after cisapride therapy, and was associated with the abolishment of bacterial overgrowth caused by gram-negative organisms in 4 out of 5 treated patients, whereas it persisted in nontreated cases. Cisapride administration to cirrhotic rats resulted in a reduction of the IBO, which is associated with a marked decrease in BT. On the other hand, cisapride facilitates the abolition of IBO caused by gram-negative organisms in cirrhotic patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/he.2000.5746

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 10

  1. Llovet, 1993, Am J Gastroenterol, 88, 388
  2. Runyon, 1995, Hepatology, 21, 1719
  3. Chesta, 1993, Hepatology, 17, 828
  4. Shindo, 1993, Am J Gastroenterol, 88, 2084
  5. Enteric bacterial flora and bacterial overgrowth syndrome. In: eds. Sleisenger & Fordtran's Gastrointestinal and Liver Disease 6th ed. Philadelphia: Saunders. 1998;1523-1535.
  6. Flexner, 1895, Johns Hopkins Hosp Bull, 6, 64
  7. Berg, 1992, J Med, 23, 217
  8. Bode, 1993, Z Gastroenterol, 31, 3
  9. Martini, 1956, Clin Sci, 16, 35
  10. McCallum, 1991, Am J Gastroenterol, 86, 135

Cited by

Sorted by citations

See all 177

Related

See all

Metadata

Authors
Pardo, A., Bartolí, R., Lorenzo-Zúñiga, V., Planas, R., Viñado, B., Riba, J., Cabré, E., Santos, J., Luque, T., Ausina, V., & Gassull, M. A.
Affiliations
Hospital Universitari Germans Trias i Pujol (ES)
ORCID
Venue
Hepatology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2000-04
Volume
31
Issue
4
Pages
858-863
ISSN
0270-9139 (ISSN-L)
DOI
10.1053/he.2000.5746
OpenAlex
W2013027212
Cited by
177
References
42
Citations by year
2026: 2 · 2025: 3 · 2024: 2 · 2023: 1 · 2022: 5 · 2021: 2 · 2020: 3 · 2019: 9 · 2018: 6 · 2017: 7 · 2016: 10 · 2015: 8 · 2014: 12 · 2013: 2 · 2012: 7
FWCI
5.83
Type
journal article
Language
en
Open access
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 5631 d)
Locations
  • Hepatology (publishedVersion)
  • PubMed (publishedVersion)
Funders
American Gastroenterological Association
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
cisapride, intestinal bacterial overgrowth, bacterial translocation, liver cirrhosis, intestinal motility, Gram-negative bacteria, orocecal transit time
MeSH terms
Adolescent, Adult, Aged, Animals, Bacteria, Female, Gastrointestinal Agents, Humans, Intestines, Liver Cirrhosis, Liver Cirrhosis, Experimental, Male, Middle Aged, Pilot Projects, Rats, Sprague-Dawley, Bacterial Translocation, Cisapride, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review